Loading...
Please wait, while we are loading the content...
Similar Documents
Spotlight on eluxadoline for the treatment of patients with irritable bowel syndrome with diarrhea
| Content Provider | Scilit |
|---|---|
| Author | Fragkos, Konstantinos C. |
| Copyright Year | 2017 |
| Abstract | Spotlight on eluxadoline for the treatment of patients with irritable bowel syndrome with diarrhea Konstantinos C Fragkos Gastrointestinal Services, University College London Hospitals, London, UK Background: Irritable bowel syndrome with diarrhea (IBS-D) has limited options for treatment currently, including mainly anti-motility medications, antispasmodics, and antidepressants. This review discusses the properties of a new drug, eluxadoline, a gut-targeting mu- and kappa-opioid receptor agonist and a delta-opioid receptor antagonist, and its efficacy and safety in patients with IBS-D. Materials and methods: A systematic review of the literature was undertaken to identify studies that had investigated eluxadoline as a treatment in IBS-D. A narrative review of other information is provided with respect to pharmacological and chemical properties. Where suitable, meta-analysis was performed with a random-effects model to produce a pooled estimate. Results: Eluxadoline showed efficacy improving stool consistency (standardized mean difference [SMD]: -0.29 at 12 weeks, p = 0.0004; -0.46 at 26 weeks, p = 0.0001), global symptoms (SMD: -0.15 at 12 weeks, p = 0.006; -0.14 at 26 weeks, p = 0.02), quality of life (SMD: 0.21 at 12 weeks, p < 0.0001; 0.16 at 26 weeks, p = 0.007), pain (SMD: -0.17 at 12 weeks, p = 0.001; -0.16 at 26 weeks, p = 0.01), and adequate relief (odds ratio [OR]: 1.99 at 12 weeks, p < 0.00001; 1.78 at 26 weeks, p < 0.0001). It also improved IBS severity and other abdominal symptoms such as bloating, discomfort, and risk of urgency and fecal incontinence. Its main side effects included constipation (OR: 3.49, p < 0.00001), vomiting (OR: 3.42, p = 0.0002), abdominal pain (OR: 1.78, p = 0.007), and nausea (OR: 1.42, p = 0.07). The overall quality of trials was satisfactory with the meta-analyses providing largely homogeneous outcomes. Conclusion: Eluxadoline’s place in clinical practice might prove useful since the pharmacological options of IBS-D are limited and eluxadoline showed a positive effect in treating the symptoms of IBS-D. Keywords: eluxadoline, irritable bowel syndrome, diarrhea, stool consistency, pain |
| Related Links | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5624596/pdf https://www.dovepress.com/getfile.php?fileID=38552 |
| Ending Page | 240 |
| Page Count | 12 |
| Starting Page | 229 |
| ISSN | 11787023 |
| e-ISSN | 11787023 |
| DOI | 10.2147/ceg.s123621 |
| Journal | Clinical and experimental gastroenterology |
| Volume Number | 10 |
| Language | English |
| Publisher | Informa UK Limited |
| Publisher Date | 2017-09-01 |
| Access Restriction | Open |
| Subject Keyword | Journal: Clinical and Experimental Gastroenterology Gastroenterology and Hepatology Eluxadoline Irritable Bowel Syndrome Diarrhea Stool Consistency Pain |
| Content Type | Text |
| Resource Type | Article |
| Subject | Gastroenterology |
